CASE REPORT
|
doi:10.20944/preprints202404.0157.v1
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
autoimmune encephalitis; checkpoint inhibitor; melanoma; pembrolizumab; adverse event
Online: 2 April 2024 (16:18:10 CEST)